Citadel Advisors
IMNP

Citadel Advisors’s Immune Pharmaceuticals Inc. IMNP Stock Holding History

Citadel Advisors’s Portfolio IMNP Stock Details IMNP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-9,340
Closed -$27K – 8439
2017
Q1 		$27K Buy
9,340
+8,180
+705% +$29.5K ﹤0.01% 7193
2016
Q4 		$4K Buy
+1,160
New +$4.76K ﹤0.01% 7168

Other funds holding IMNP

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return
AFM
Anson Funds Management Dallas, Texas $2.29B AUM 370.24% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
AG
Advisor Group Phoenix, Arizona $14.5B AUM 24.86% 1-Year Est. Return
FDCDDQ
Federation des caisses Desjardins du Quebec Levis, Quebec, Canada $27.8B AUM 31.66% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Citadel Advisors's IMNP Position: Q2 2017 in Review

Citadel Advisors sold out of Immune Pharmaceuticals Inc. (IMNP) in Q2 2017, closing a stake of 9,340 shares — an estimated $27K sold.

Citadel Advisors first reported a position in IMNP in Q4 2016 and held it in 2 quarters. The position peaked at $27K in Q1 2017. 18 funds tracked by Wall St. Rank hold IMNP as of Q2 2017.

  • Citadel Advisors reported no remaining Immune Pharmaceuticals Inc. position as of Q2 2017 after selling out during the quarter.
  • Citadel Advisors sold 9,340 Immune Pharmaceuticals Inc. shares in Q2 2017, an estimated $27K.
  • Citadel Advisors first reported a position in Immune Pharmaceuticals Inc. in Q4 2016 and held it in 2 quarters.
  • Citadel Advisors's Immune Pharmaceuticals Inc. position peaked at $27K in Q1 2017.
  • 18 funds tracked by Wall St. Rank held Immune Pharmaceuticals Inc. as of Q2 2017.

Based on Citadel Advisors's 13F filing for Q2 2017, filed 11 Aug 2017.